These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 19047819)
1. Comparison of in vivo nephrotoxicity in the rabbit by a pyrrolidinyl-thio Carbapenem CW-270031. Kim JM; Ha JR; Oh SW; Kim HG; Lee JM; Kim BO; Lee DG; Lee SH; Kim JG J Microbiol Biotechnol; 2008 Nov; 18(11):1768-72. PubMed ID: 19047819 [TBL] [Abstract][Full Text] [Related]
2. CW-270033, a novel pyrrolidinyl-thio carbapenem, has potent antimicrobial activity in vitro and in vivo. Kim J; Ha JR; Oh SW; Kim HG; Lee JM; Lee DG; Lee SH; Kim JG Biol Pharm Bull; 2007 Mar; 30(3):575-9. PubMed ID: 17329859 [TBL] [Abstract][Full Text] [Related]
3. The risk of seizures among the carbapenems: a meta-analysis. Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302 [TBL] [Abstract][Full Text] [Related]
4. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB; Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776 [TBL] [Abstract][Full Text] [Related]
5. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial. Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A; J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059 [TBL] [Abstract][Full Text] [Related]
6. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084 [TBL] [Abstract][Full Text] [Related]
7. Safety evaluation of meropenem in animals: studies on the kidney. Topham JC; Murgatroyd LB; Jones DV; Goonetilleke UR; Wright J J Antimicrob Chemother; 1989 Sep; 24 Suppl A():287-306. PubMed ID: 2681127 [TBL] [Abstract][Full Text] [Related]
8. [Tolerance and safety of carbapenems: the use of meropenem]. Lizasoaín M; Noriega AR Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():73-7. PubMed ID: 9410074 [TBL] [Abstract][Full Text] [Related]
9. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Day IP; Goudie J; Nishiki K; Williams PD Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010 [TBL] [Abstract][Full Text] [Related]
10. Lucasti et al in the May 2008 issue of Clinical Therapeutics. Porath AD Clin Ther; 2008 Oct; 30(10):1934; author reply 1934-6. PubMed ID: 19014850 [No Abstract] [Full Text] [Related]
11. Is it safe to use carbapenems in patients with a history of allergy to penicillin? Sodhi M; Axtell SS; Callahan J; Shekar R J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083 [TBL] [Abstract][Full Text] [Related]
12. Carbapenems in serious infections: a risk-benefit assessment. Norrby SR Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843 [TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity of carbapenem antibacterials. Norrby SR Drug Saf; 1996 Aug; 15(2):87-90. PubMed ID: 8884160 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Moon YS; Chung KC; Gill MA Clin Infect Dis; 1997 Feb; 24 Suppl 2():S249-55. PubMed ID: 9126700 [TBL] [Abstract][Full Text] [Related]
15. Comparative study of certain antibiotics on epileptogenic property, including (1Rpi, 5S, 6S)-2-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazolium-6-yl)] thio-6-[(R)-1-hydroxyethyl]-1-methyl-carbapenem-3-carboxylate (LJC10627), a carbapenem antibiotic with broad antimicrobial spectrum. Kamei C; Kitazumi K; Tsujimoto S; Yoshida T; Tasaka K J Pharmacobiodyn; 1991 Sep; 14(9):509-17. PubMed ID: 1779405 [TBL] [Abstract][Full Text] [Related]
16. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549 [TBL] [Abstract][Full Text] [Related]
17. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937 [TBL] [Abstract][Full Text] [Related]
18. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Hirouchi Y; Naganuma H; Kawahara Y; Okada R; Kamiya A; Inui K; Hori R Jpn J Pharmacol; 1994 Sep; 66(1):1-6. PubMed ID: 7861655 [TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia. Tang HJ; Chuang YC; Ko WC; Chen CC; Shieh JM; Chen CH; Lee NY; Chiang SR Int J Infect Dis; 2012 Jan; 16(1):e34-40. PubMed ID: 22088863 [TBL] [Abstract][Full Text] [Related]
20. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Horiuchi M; Kimura M; Tokumura M; Hasebe N; Arai T; Abe K Toxicology; 2006 May; 222(1-2):114-24. PubMed ID: 16549226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]